Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.68 |
| ▸ | MMP13 | P45452 | 16/20 | 0.68 |
| ▸ | MMP2 | P08253 | 13/20 | 0.68 |
| ▸ | MMP14 | P50281 | 11/20 | 0.68 |
| ▸ | MMP1 | P03956 | 6/20 | 0.53 |
| ▸ | MMP9 | P14780 | 5/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788797 | 0.85 | MMP13 (0.71) | ADAM17MMP13MMP2MMP14MMP1 | |
| SCHEMBL6791098 | 0.79 | ADAM17 (0.61) | ADAM17MMP13MMP2MMP14MMP1 | |
| SCHEMBL3946150 | 0.77 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP14MMP1 | |
| SCHEMBL7681841 | 0.76 | MMP13 (0.59) | ADAM17MMP13MMP2MMP14MMP1 | |
| SCHEMBL20137565 | 0.72 | TSHR (0.49) | ADAM17MMP13MMP2MMP14 | |
| SCHEMBL6784917 | 0.72 | MMP13 (0.54) | ADAM17MMP13MMP2MMP14MMP1 | |
| SCHEMBL6264848 | 0.70 | ADAM17 (0.78) | ADAM17MMP13MMP2MMP14MMP1 | |
| SCHEMBL7868817 | 0.70 | PRMT1 (0.53) | — | |
| SCHEMBL2344497 | 0.69 | MMP13 (0.51) | ADAM17MMP13MMP2MMP14 | |
| SCHEMBL11889653 | 0.69 | NPC1 (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097487-A1 | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds | G.D. SEARLE & CO. | 2004-05-20 | — | — | US | disclosed |
| US-6638952-B1 | Matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097487-A1 | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds | MMP1, MMP2, MMP10 | ADAM17 24/4885MMP13 10/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.